Compugen Sells Royalty Interest for $65M
Ticker: CGEN · Form: 6-K · Filed: Dec 17, 2025 · CIK: 1119774
| Field | Detail |
|---|---|
| Company | Compugen Ltd (CGEN) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $65 million, $25 million, $90 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: licensing, royalty sale, collaboration
Related Tickers: CGEN
TL;DR
Compugen cashed out $65M from AstraZeneca for a piece of its rilvegostomig royalties.
AI Summary
On December 16, 2025, Compugen Ltd. amended its license agreement with MedImmune Limited, a member of the AstraZeneca Group. Compugen sold a portion of its existing royalty interest in rilvegostomig to AstraZeneca for an upfront payment of $65 million.
Why It Matters
This transaction provides Compugen with immediate capital, potentially impacting its research and development funding and future growth prospects.
Risk Assessment
Risk Level: low — The filing is a routine amendment to an existing license agreement and does not indicate significant new risks for Compugen.
Key Numbers
- $65 million — Upfront Payment (Received by Compugen from AstraZeneca for royalty interest.)
Key Players & Entities
- Compugen Ltd. (company) — Registrant and seller of royalty interest
- MedImmune Limited (company) — Party to the license agreement amendment
- AstraZeneca Group (company) — Parent company of MedImmune Limited
- rilvegostomig (drug) — Product associated with the royalty interest
- $65 million (dollar_amount) — Upfront payment received by Compugen
- December 16, 2025 (date) — Date of the license agreement amendment
FAQ
What specific portion of the royalty interest did Compugen sell?
The filing states Compugen sold 'a portion' of its existing royalty interest but does not specify the exact percentage or terms of that portion.
What is the significance of rilvegostomig?
Rilvegostomig is the drug for which Compugen held a royalty interest that was partially sold to AstraZeneca.
What was the original license agreement date?
The original license agreement between Compugen and MedImmune Limited was dated March 30, 2018.
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, reporting material information to the SEC.
Does this amendment affect Compugen's future development of rilvegostomig?
The filing does not specify any impact on Compugen's future development activities related to rilvegostomig; it only concerns the sale of a royalty interest.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2025-12-17 07:05:10
Key Financial Figures
- $65 million — royalty interest in rilvegostomig for a $65 million upfront payment, due within five (5) bu
- $25 million — se Application ("BLA") was increased by $25 million. The foregoing summary of the Amendmen
- $90 Million — ture Royalties to AstraZeneca for Up to $90 Million" # Portions of this exhibit (indica
Filing Documents
- zk2534122.htm (6-K) — 12KB
- exhibit_10-1.htm (EX-10.1) — 17KB
- exhibit_99-1.htm (EX-99.1) — 15KB
- image0.jpg (GRAPHIC) — 432KB
- 0001178913-25-004077.txt ( ) — 640KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. COMPUGEN LTD. Date: December 17, 2025 By: /s/ Eran Ben Dor Eran Ben Dor General Counsel